One of the major factors for efficacy of a chmotherapeutic drug is its activity to induce apoptosis of tumor cells. Doxorubicin and daunorubicin, radiomimetic anthracycline-group drugs, have been used for chemotherapy for about 30 years. Here we established the colorectal tumor and osteosarcoma cells in which Bax expression can be induced by the treatment of isopropyl-b -D-thiogalactopyranoside, and examined the effect of the Bax overexpression on the cell death caused by these drugs. While the Bax overexpression neither affected growth nor morphology of the undamaged cells, it enhanced the cell death caused by these drugs. Increase in cellular nucleus fragmentation and DNA ladder formation indicates that the Bax-enhanced cell death is due to enhanced apoptosis of the drug-treated cells. The enhanced cell death was not observed when the cells were irradiated with X-ray or treated with other chemotherapeutic agents we examined. These results indicate that Bax may have a specific role to enhance the efficacy of chemothrapy with anthracycline-group agents.
INTRODUCTION
Activity to induce apoptosis is one of the major factors for efficacy of chemotherapeutic agents. One of the proteins to determine liability of cells to undergo apoptosis is Bcl-2 family proteins. At least 15 members of the family have been identified in mammalian cells 1, 2) .
Various homodimers and heterodimers formed by these proteins can either promote or inhibit apoptosis. The homodimer of Bcl-2 protein blocks apoptosis following a variety of stimuli such as chemotherapeutic agents, radiation and withdrawal of growth factors, and confers a death-sparing effect mainly on hematopoietic cell lines. Bax forms homodimers and heterodimers with Bcl-2 and interferes with the apoptosis-repressor activity of Bcl-2 3) . Other pro-apoptotic members of this family include Bcl-x S , Bad, Bak, Bik, BID and Hrk. Other anti-apoptotic members of this family include Bcl-x L , Bcl-w, Mcl-1, Bag-1 and Bfl-1. The liability of a cell to undergo apoptosis is dependent on the proportion of these various positive and negative regulators within the cell. Different tumor cells respond to different chemotherapeutic agents in different ways. In some tumor cells, Bax gene expression plays an important role on apoptosis caused by some chemotherapeutic agents. Overexpression of Bax enhances epirubicin, cisplatin and etoposideinduced death of breast cancer cells 4, 5) , paclitaxel and vincristine-induced death of ovarian tumor cells 6) , and araC and SN-38-induced death of erythroleukemia cells 7) . However, Bax does not affect etoposide-induced death of ovarian tumor and erythroleulemia cells 6, 7) .
Doxorubicin (the synonym of adriamycin) and daunorubicin are anthracycline group anti-cancer chemotherapeutic drugs that have been used clinically for about 30 years 8) . They bind to DNA by intercalation, and subsequently cause RNA synthesis inhibition, DNA single strand breaks and cell cycle arrest at the G2/M phase. These phenomena are also observed after cells are irradiated with X-ray, therefore these drugs are called radiomimics. The tumor cells arrested at the G2/M phase by these drugs undergo apoptosis 9 -11) . Bax overexpression enhances doxorubicin-induced death of ovarian tumor and erythroleukemia cells 6, 7) .
The complexity of the effect of Bax expression on apoptosis of tumor cells suggests that cells have different pathways to undergo apoptosis. The pathways may depend on types of chemothrapeutic agents, genetic background of the cells or originated tissue type of the cells. To compare characteristics of the tumor cells with and without Bax expression, the identical genetic background of the cells is prerequisite. Therefore, we established the cell clones from two cell types, colorectal tumor and osteosarcoma, of which Bax expression can be controlled by the LacSwitch 12) . Using this cell systems, we show that Bax overexpression itself does not cause cell death, but enhances doxorubicin and daunorubicin-induced apoptotic cell death.
MATERIALS AND METHODS

Establishment of tumor cell lines that can express Bax by the LacSwitch
As overexpression of exogenously introduced Bax may kill cells, we used the LacSwitch-inducible mammalian expression system to regulate Bax expression in cells. Details of the LacSwitch system construction were described previously 13) . Briefly, human
Baxa cDNA (0.6 kb) was ligated to a NotI site that locates downstream the RSV-LTR promoter that carries bacterial LacI repressor-binding sites in the plasmid pOPRSVI, and the constructed plasmid was named pOPRSVIBax. The plasmid was introduced to human colorectal tumor (DLD-1) and osteosarcoma (SAOS-2) cells which have exogenously-introduced bacterial LacI gene and constitutively express the LacI protein. In the cells, Baxa transcription was suppressed by LacI in ordinary culture medium, but the transcription was initiated when isopropyl-b -D-thiogalactopyranoside (IPTG) was added to the medium. DLD-1 cells have only mutated p53 gene 14) , and SAOS-2 cells are deficient in p53 gene 15) . After the cells were transfected with pOPRSVIBax, neomycin-resistant cell clones were randomly isolated, and Bax expression induced by IPTG (5 mM) in the clones was confirmed by the Western blotting. The cell clones DLD1-Bax10 and SAOS-Bax2 were used for further experiments.
Northern and Western blot analyses DLD1-Bax10 and SAOS-Bax2 cells were cultured in medium with or without IPTG (5 mM), and RNA was isolated from the cells by the RNeasy Total RNA Kit (Qiagen, Hilden, Germany). The RNA (20 mg) was separated with 1% agarose-formaldehyde gel electrophoresis, and transferred to Biodyne B membrane (Pall, Glen Cove, NY). The RNA on the membrane was hybridized with Baxa cDNA labelled with [a - 
Cell growth analysis
Approximately 10 5 DLD1-Bax10 or SAOS-Bax2 cells were seeded per 6 cm-dish, and culture medium was replaced by the one with or without IPTG (5 mM) next day (day 1). The cell number was counted everyday until day 10.
Measurement of sensitivity to chemotherapeutic agents
Appropriate numbers of DLD1-Bax10 or SAOS-Bax2 cells were seeded in 6-cm dishes and cultured in the medium with or without IPTG (5 mM) for 24 h. The cells were incubated with serum-free medium containing doxorubicin, daunorubicin or other chemothrapeutic agents for 1 h at 37°C, and then with ordinary medium with or without IPTG (5 mM) for 24 h. The cells were further incubated in the ordinary medium without IPTG for about 10 days until colonies were formed. The ratio of the colony numbers of treated cells to those of untreated cells was shown as survival.
Detection of apoptosis
DLD1-Bax10 or SAOS-Bax2 cells were inoculated in 3.5 cm-dishes and cultured in the medium with or without IPTG (5 mM) for 24 h. The cells were cultured in serum-free medium containing doxorubicin or daunorubicin (2 mg/ml) for 1 h at 37°C, and further cultured in ordinary medium with or without IPTG (5 mM) for 1-3 days. They were washed with PBS, stained with the DNA-binding dye Hoechst 33258 (0.5 mg/ml), and observed under a fluorescence microscope. Cells showing condensed nuclear morphology and nuclear lobulations were regarded as apoptotic 13) . DNA was extracted from the cells 48 hours after the drug treatment as above using the Apoptosis Ladder Detection Kit (Wako, Osaka, Japan), separated by agarose gel electrophoresis and stained with SYBR Green I (Molecular Probes, Eugene, OR).
RESULTS
Bax expression induced by IPTG treatment
Levels of Bax mRNA and protein were measured by Northern and Western blotting, respectively (Fig. 1) . The Bax mRNA level increased rapidly by the IPTG treatment and reached the plateau level about 5 and 12 h later in DLD-Bax10 and SAOS-Bax2 cells, respectively. The level of Bax protein increased more slowly than the level of Bax mRNA and reached the plateau level 12 h later in the both cells. The relative levels of Bax mRNA and protein 24 h after the IPTG treatment are 2.4 and 3.6 times, respectively, higher than the untreated levels in DLD-Bax10 cells. Those of Bax mRNA and protein 24 h after the treatment are 3.1 and 4.2 times, respectively, higher than the control levels in SAOS-Bax2 cells. The Bax protein level decreased very slowly in both cells after removal of IPTG that had been present in the culture medium for 24 h.
No effect of Bax overexpression on cell growth
The effect of Bax overexpression on growth of DLD-Bax10 and SAOS-Bax2 cells was examined (Fig. 2) . The growth rate of the both cells was not changed by the presence of IPTG in the medium, indicating that Bax overexpression does not affect the cell growth. DLD-Bax10 cells proliferated more rapidly than SAOS-Bax2 cells, which was not due to the Bax expression level.
Sensitization of cells to doxorubicin and daunorubicin by Bax overexpression
The effect of Bax overexpression on sensitivities of DLD-Bax10 and SAOS-Bax2 cells to chemotherapeutic drugs, doxorubicin and daunorubicin was measured by colony-formation of the drug-treated cells (Fig. 3) . Survival of daunorubicin or doxorubicin-treated cells was reduced by the presence of IPTG in the medium, indicating that Bax overexpression enhances sensitivity of the cells to these drugs. However, the Bax overexpression does not affect the sensitivity of the cells to X-ray, etoposide, cisplatin and bleomycin (data not shown).
Enhancement of doxorubicin and daunorubicin-induced apoptosis by Bax overexpression
To examine the effect of Bax overexpression on doxorubicin and daunorubicin-induced apoptosis, a fraction of the cells having lobulated or fragmented nuclei was scored after the treatment of the drugs followed by incubation in medium with or without IPTG (Fig. 4) . The drug-induced apoptosis of DLD-Bax10 and SAOS-Bax2 cells was enhanced by IPTG. The effect of Bax overexpression on the drug-induced apoptosis was also examined by DNA ladder formation in the agarose gel electrophoresis. The drug-induced apoptotic DNA ladders were increased by the IPTG treatment (Fig. 5) . These results indicate that Bax overexpression enhances doxorubicin and daunorubicin-induced apoptotic cell death. 
DISCUSSION
We established the LacSwitch-induced Bax expression cell system that can enhance the cellular Bax protein level approximately 3-4 times higher than the control level. In spite of the high expression of the Bax protein, the growth rates of both DLD-Bax10 and SAOS-Bax 2 cells were not affected. Morphology of the both cells was also unchanged by the high Bax expression (data not shown). These results indicate that the Bax overexpression does not cause apoptosis by itself. Bax would need a trigger from outside of the cells to cause apoptosis.
One of the merits of our LacSwitch-induced Bax expression system is that effects of the Bax overexpression can be evaluated in the cells with an identical genetic back ground. A similar cell system for the Bax overexpression induced by tetracyclin withdrawal is established using MCF-7 breast cancer cells by Wagener et al 4) . However, they did not examine the effect of the Bax overexpression on doxorubicin or daunorubicin-induced cell death. In the LacSwitch system, Bax overexpression enhances sensitivity of DLD-Bax10 and SAOS-Bax 2 cells to doxorubicin and daunorubicin. However, we found that the Bax overexpression does not affect the sensitivity of the cells to X-ray, etoposide, cisplatin and bleomycin (data not shown). Doxorubicin and daunorubicin are structurally similar compounds that have anthracycline rings of which difference is whether the 14th carbon is hydroxylated or not 8) . Other reports show that sensitivity of ovarian tumor SW626 and eruthroleukemia K562 cells to doxorubicin is also enhanced by Bax overexpression 6, 7) . Therefore, cell death by anthracycline group chemothrapeutic agents may be commonly mediated by Bax expression in most cancer cells. No sensitization of the cells to etoposide and cisplatin by Bax overexpression in our study and the contradictory results to ours using different cells 5, 17) suggest that other pathways to lead to cell death are present following the treatment with these agents. As DLD-1 and SAOS-2 cells used in this study lack normal p53 protein, the cell death pathway may be p53-dependent. Many cell death pathways specific to the type of damage and dependent on the cellular p53 status 18) would be present in human cells.
The death of DLD-Bax10 and SAOS-Bax2 cells enhanced by the Bax overexpression should be regarded as apoptosis based on enhancement of nuclear lobulation and fragmentation of the cells and DNA ladder formation (Figs. 4 and 5) . Other reports show that the doxorubicin treatment causes cell cycle arrest at the G2/M phase after proceeding the cell cycles a few times, and subsequently the cells undergo apoptosis 10, 11, 19) . These results indicate that some types of mitotic death are apoptosis like all interphase deaths. Sawada and coworkers 20, 21) demonstrated that g -ray-caused mitotic death of some gastric epithelial tumor and leukaemia cells are apoptosis. In our study, the day-dependent increase in a fraction of apoptotic cells (Fig. 4) of which doubling time is about 24 h suggests that mitotic cell death occurred after the doxorubicin or daunorubicin treatment, and that the Bax overexpression enhances the mitotic death. We previously showed that p21 (Waf1, Cip1) overexpression blocks doxorubicin-induced apoptosis of DLD-1 cells, and inhibition of cyclin-dependent kinase is required for the block of the apoptosis 13) . Both p21 and Bax expressions are positively regulated by p53 expression although they have opposite functions 19, 22 -24) . To elucidate the regulation mechanism of these genes after the cells are treated with chemotherapeutic drugs must be important for raising efficacy of chemotherapy.
